[A clinical study of decreased bone density in the patients treated with long-term luteinizing hormone releasing hormone analogue (LHRH-a)--the risk of iatrogenic osteoporosis due to treatment of carcinoma of prostate].

@article{Suzuki1998ACS,
  title={[A clinical study of decreased bone density in the patients treated with long-term luteinizing hormone releasing hormone analogue (LHRH-a)--the risk of iatrogenic osteoporosis due to treatment of carcinoma of prostate].},
  author={Yasuyoshi Suzuki and Keiko Aikawa and Yukihiko Oishi and Haruki Yamazaki and Tetsuro Onishi and Masayasu Suzuki and Toru Kobari and Katsuhisa Endo and Shuichi Yanada and Noboru Kato and Yasushi Yoshino and Tetsuro Toyoda Akiyoshi Wada and Masataka Ueda and Satoru Takasaka and Kohei Akazawa},
  journal={Nihon Hinyokika Gakkai zasshi. The japanese journal of urology},
  year={1998},
  volume={89 12},
  pages={961-6}
}
BACKGROUND It is well known that androgens play an important role in bone metabolism and male hypogonadism induce osteoporosis. Luteinizing hormone-releasing hormone analogue (LHRH-a) which is essential for conservative therapy of prostatic carcinoma (CaP) ultimately reduces circulating testosterone to castration levels. The purpose of this study was to determine the risk of decrease of bone mineral density in men receiving LHRH-a for CaP. PATIENTS AND METHODS Fifty-three man with CaP aged 63… CONTINUE READING